In the April 22, 2015, Federal Register, FDA determined, in response to a citizen petition, that oxytocin in dextrose 5% injection products were not withdrawn from sale for reasons of safety or effectiveness. This determination allows FDA to approve an abbreviated new drug application ("ANDA") for these oxytocin drug products, if all other legal and regulatory requirements are met.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
